Citation Impact
Citing Papers
Drug Resistance and Pseudoresistance
2012
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
2019
IL-1 Blockade in Autoinflammatory Syndromes
2014
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus
2015
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
2016
In situ click chemistry generation of cyclooxygenase-2 inhibitors
2017 Standout
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
Management of cancer pain
1999 Standout
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
2005
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Adaptive immunity in atherogenesis: new insights and therapeutic approaches
2013
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
2019 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Pharmacodynamics, Chiral Pharmacokinetics, and Pharmacokinetic‐Pharmacodynamic Modeling of Fenoprofen in Patients With Diabetes Mellitus
2006
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
2000 Standout
Hallmarks of aging: An expanding universe
2023 Standout
New Antithrombotic Drugs
2012
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary
2011
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
2017
Unstable Angina Pectoris
2000
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
Enantioselective rhodium-catalyzed addition of arylboronic acids to trifluoromethyl ketones
2006 StandoutNobel
Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice
2018
Gender differences in symptoms of myocardial ischaemia
2011
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs
2014
The IL-1 family of cytokines and receptors in rheumatic diseases
2019
Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes
2003
COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs
2000
Platelet Activation and Atherothrombosis
2007 Standout
Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)
2014
Antiplatelet Drugs
2012
Coxibs and Cardiovascular Disease
2004 Standout
Non-alcoholic fatty liver disease
2021 Standout
Determinants of the interindividual variability in response to antiplatelet drugs
2005
Antiplatelet Drugs
2008
3-Year Follow-Up of Patients With Coronary Artery Spasm as Cause of Acute Coronary Syndrome
2011
Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress
2014
Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2
2000 Standout
SYSTEMIC INTERLEUKIN 1β INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY
2015
A Test in Context
2016
Aspirin and Antiplatelet Agent Resistance
2010
Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside
2018
The immunomodulating role of exercise in metabolic disease
2014
Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease
2004
Chronic tissue inflammation and metabolic disease
2021
Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension
2010
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
2021
Low-Dose Aspirin for the Prevention of Atherothrombosis
2005
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
2001
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
2019
Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
2007
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Inflammasomes: mechanism of action, role in disease, and therapeutics
2015 Standout
COX-2 inhibitors
1999 Standout
Inflammation in Obesity and Diabetes: Islet Dysfunction and Therapeutic Opportunity
2013
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
Antiplatelet agents for the treatment and prevention of atherothrombosis
2011
Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease
2021
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Cellular senescence: from physiology to pathology
2014 Standout
The Activation of Carboxylic Acids via Self-Assembly Asymmetric Organocatalysis: A Combined Experimental and Computational Investigation
2016 StandoutNobel
Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes
2019
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Nonsteroidal Anti-Inflammatory Drugs and the Heart
2014
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves
2017
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Salicylate (Salsalate) in Patients With Type 2 Diabetes
2013
Diagnosis and Treatment of Hip and Knee Osteoarthritis
2021 Standout
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial
2018
Depression and Coronary Heart Disease
2008 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement
2020
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis
2019
Targeting Interleukin-1 in Heart Disease
2013
Spermidine in health and disease
2018 StandoutScience
Association of Subclinical Inflammation With Polyneuropathy in the Older Population
2013
Effects of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta‐Analysis
2017
Aspirin and Antiplatelet Agent Resistance
2010
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers
2000
NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice—Brief Report
2017
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases
2014 Standout
CYCLOOXYGENASES 1 AND 2
1998 StandoutNobel
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
2020 Standout
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
2017
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
2019
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients
2019
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
2009 Standout
From C-Reactive Protein to Interleukin-6 to Interleukin-1
2016
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1βvia the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients
2015
Randomized pilot study of nimesulide treatment in Alzheimer’s disease
2002
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Novel Antiatherosclerotic Therapies
2019
Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?
2018
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves
2018
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab
2022
Interleukin-1 signaling contributes to acute islet compensation
2016
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
1999 Nobel
Works of Giulia Renda being referenced
Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen
2012
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
2017
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease
2006
Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed Hypertension
2008
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
2017
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease
2006
Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings*
1998
Rapid Decline of Collateral Circulation Increases Susceptibility to Myocardial Ischemia
2006
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences
2010
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
2018
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
2005
Platelet Activation and Inhibition in Unstable Coronary Syndromes
1997
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
2018
Transient microvascular vasoconstriction: a possible cause of unstable angina.
2000
Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs.
1997
OUTCOMES IN 2824 PATIENTS WITH VALVULAR HEART DISEASE TREATED WITH EDOXABAN OR WARFARIN IN THE ENGAGE AF-TIMI 48 TRIAL
2016
Response to “Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance”
2007
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
2018
Dose-Dependent Inhibition of Platelet Cyclooxygenase-1 and Monocyte Cyclooxygenase-2 by Meloxicam in Healthy Subjects
1999